Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Location
Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 689 % -25.3%
Debt-to-equity -206 % +17.6%
Return On Equity 46.2 % +357%
Return On Assets -43.7 % -548%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.99M shares 0%
Common Stock, Shares, Outstanding 6.99M shares 0%
Entity Public Float 12.9M USD -65%
Common Stock, Value, Issued 699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.57M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.57M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.57M USD -62%
General and Administrative Expense 9.07M USD -7.98%
Operating Income (Loss) -14.6M USD +40.2%
Net Income (Loss) Attributable to Parent -14M USD -324%
Earnings Per Share, Basic -1 USD/shares -363%
Earnings Per Share, Diluted -1 USD/shares -363%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.3M USD -53.7%
Assets, Current 13M USD -53.4%
Property, Plant and Equipment, Net 1.36K USD -80%
Goodwill 14.9M USD 0%
Assets 28.1M USD -34.4%
Accounts Payable, Current 944K USD +70.7%
Liabilities, Current 2.67M USD -40.4%
Liabilities 62.7M USD -2.81%
Retained Earnings (Accumulated Deficit) -405M USD -3.59%
Stockholders' Equity Attributable to Parent -34.6M USD -59.6%
Liabilities and Equity 28.1M USD -34.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.07M USD +33.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 6.99M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.07M USD +33.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.4M USD -53.5%
Deferred Tax Assets, Valuation Allowance 96.1M USD -0.84%
Deferred Tax Assets, Gross 96.1M USD -0.84%
Deferred Tax Assets, Operating Loss Carryforwards 42.9M USD +24.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 1.12M USD -33.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%